These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. Paré G; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Hirsh J; Simonsen K; Bhatt DL; Fox KA; Eikelboom JW N Engl J Med; 2010 Oct; 363(18):1704-14. PubMed ID: 20979470 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome p-450 polymorphisms and response to clopidogrel. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325 [TBL] [Abstract][Full Text] [Related]
7. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y; JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249 [TBL] [Abstract][Full Text] [Related]
8. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Zabalza M; Subirana I; Sala J; Lluis-Ganella C; Lucas G; Tomás M; Masiá R; Marrugat J; Brugada R; Elosua R Heart; 2012 Jan; 98(2):100-8. PubMed ID: 21693476 [TBL] [Abstract][Full Text] [Related]
9. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. Li Y; Tang HL; Hu YF; Xie HG J Thromb Haemost; 2012 Feb; 10(2):199-206. PubMed ID: 22123356 [TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of response to clopidogrel and cardiovascular events. Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L; N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. Holmes MV; Perel P; Shah T; Hingorani AD; Casas JP JAMA; 2011 Dec; 306(24):2704-14. PubMed ID: 22203539 [TBL] [Abstract][Full Text] [Related]
13. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260 [TBL] [Abstract][Full Text] [Related]
14. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397 [TBL] [Abstract][Full Text] [Related]
15. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656 [TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880 [TBL] [Abstract][Full Text] [Related]
17. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
18. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980 [TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921 [TBL] [Abstract][Full Text] [Related]
20. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G Platelets; 2015; 26(6):558-62. PubMed ID: 25207801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]